Group 1 - The core viewpoint of the collaboration between Dongyangguang Pharmaceutical and Jingtai Technology is to establish a joint venture focused on AI-driven drug development, aiming to create a comprehensive AI drug research engine and facilitate technology export [1][2] - The partnership will leverage Jingtai Technology's expertise in AI and Dongyangguang's experience in autoimmune diseases to accelerate drug discovery and clinical translation, particularly through the development of a leading PB-PK model [1][2] - The collaboration aims to build an AI supercomputing platform that supports data development and ecosystem sharing, transforming data assets and AI products into a "Model as a Service" (MaaS) business model [2] Group 2 - The current challenges in drug development include "data silos" and high barriers to entry, where traditional pharmaceutical companies have extensive clinical data but lack advanced algorithm development capabilities, while AI platform companies possess cutting-edge technology but lack access to real-world data [3] - The deep collaboration between Dongyangguang Pharmaceutical and Jingtai Technology is seen as a necessary evolution in the industry, creating a foundational operating system for AI drug development [3] - This collaboration is expected to enhance the competitiveness of the Chinese pharmaceutical ecosystem in the international market, supported by "Chinese data + Chinese algorithms + Chinese manufacturing (robots)" [3]